- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | TRANSTHERA-B (02617): PROPOSED ADOPTION OF THE H SHARE AWARD SCHEME | 1 | HKEx | ||
| 31.03. | TRANSTHERA-B (02617): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | - | HKEx | ||
| 31.03. | TRANSTHERA-B (02617): CHANGE OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND RESIGNATION OF NON-EXECUTIVE DIRECTOR | - | HKEx | ||
| 31.03. | TRANSTHERA-B (02617): DISSOLUTION OF THE SUPERVISORY COMMITTEE AND PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION, THE RULES OF PROCEDURE OF SHAREHOLDERS' ... | 1 | HKEx | ||
| 31.03. | TRANSTHERA-B (02617): ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2025 | 1 | HKEx | ||
| 19.03. | TRANSTHERA-B (02617): DATE OF BOARD MEETING | 2 | HKEx | ||
| 18.03. | TRANSTHERA-B (02617): VOLUNTARY ANNOUNCEMENT FIRST PATIENT DOSED IN PHASE II CLINICAL TRIAL OF TINENGOTINIB IN COMBINATION WITH FULVESTRANT FOR THE TREATMENT ... | 1 | HKEx | ||
| TRANSTHERA SCIENCES Aktie jetzt für 0€ handeln | |||||
| 09.03. | TRANSTHERA-B (02617): VOLUNTARY ANNOUNCEMENT INCLUSION OF THE COMPANY AS A CONSTITUENT OF THE HANG SENG INDEX SERIES | 1 | HKEx | ||
| 20.01. | TRANSTHERA-B (02617): NEXT DAY DISCLOSURE RETURN | 1 | HKEx | ||
| 20.01. | TRANSTHERA-B (02617): COMPLETION OF PLACING OF NEW H SHARES UNDER THE GENERAL MANDATE | 2 | HKEx | ||
| 13.01. | TRANSTHERA-B (02617): PLACING OF NEW H SHARES UNDER GENERAL MANDATE | 5 | HKEx | ||
| 12.01. | TRANSTHERA-B (02617): VOLUNTARY ANNOUNCEMENT PRESENTATION OF CLINICAL DATA ANALYSIS OF TINENGOTINIB MONOTHERAPY IN PATIENTS WITH ADVANCED CHOLANGIOCARCINOMA ... | 1 | HKEx | ||
| 12.01. | XFRA NEW INSTRUMENTS AVAILABLE ON 12.01.2026 | 545 | Xetra Newsboard | The following instruments on XETRA do have their first trading 12.01.2026 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 12.01.2026
Aktien
1 CA2924833023 Enablence Technologies... ► Artikel lesen | |
| 19.12.25 | TransThera Sciences (Nanjing) Inc.: New Drug Application For Tinengotinib Tablets Accepted By The National Medical Products Administration | 202 | PR Newswire | NANJING, China and GAITHERSBURG, Md., Dec. 18, 2025 /PRNewswire/ -- TransThera Sciences Nanjing, Inc. (the "TransThera") announced that the new drug application... ► Artikel lesen | |
| 19.12.25 | TRANSTHERA-B (02617): VOLUNTARY ANNOUNCEMENT NEW DRUG APPLICATION FOR TINENGOTINIB TABLETS ACCEPTED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION | 2 | HKEx | ||
| 17.12.25 | TRANSTHERA-B (02617): VOLUNTARY ANNOUNCEMENT PUBLICATION OF CLINICAL RESULTS OF OUR CORE PRODUCT TINENGOTINIB AGAINST CHOLANGIOCARCINOMA | - | HKEx | ||
| 03.12.25 | TRANSTHERA-B (02617): VOLUNTARY ANNOUNCEMENT INCLUSION OF TINENGOTINIB TABLETS IN THE LIST OF PRODUCTS FOR PRIORITY REVIEW BY THE NATIONAL MEDICAL PRODUCTS ... | - | HKEx | ||
| 03.11.25 | Neurocrine pens $880M deal with China's TransThera for red-hot immunology target | 12 | FierceBiotech | ||
| 03.11.25 | TRANSTHERA-B (02617): VOLUNTARY ANNOUNCEMENT COLLABORATION WITH NEUROCRINE | 4 | HKEx | ||
| 20.10.25 | TRANSTHERA-B (02617): INSIDE INFORMATION ANNOUNCEMENT PROPOSED IMPLEMENTATION OF THE H SHARE FULL CIRCULATION BY THE COMPANY | 1 | HKEx |
20 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 35,045 | +0,04 % | QIAGEN N.V.: Qiagen Announces Form 20-F Annual Report Filing for 2025 Results | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended... ► Artikel lesen | |
| IMMUNOVANT | 24,500 | -4,48 % | IMVT Stock Falls 2.4% as Batoclimab Misses Late-Stage Study Endpoints | ||
| DYNE THERAPEUTICS | 18,680 | -3,51 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces New Positive Cardiopulmonary Results from DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD) | - New analyses out to 24-months showed improvement in heart and lung function compared to expected declines in DMD natural history - - Data expand on previously reported results demonstrating that... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 45,320 | -0,66 % | H.C. Wainwright reiterates Enliven Therapeutics stock rating on Terns deal details | ||
| ZENTALIS PHARMACEUTICALS | 6,630 | +50,17 % | Jefferies raises Zentalis stock price target on ovarian cancer trial data | ||
| VERA THERAPEUTICS | 45,000 | +9,92 % | Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| ALUMIS | 23,050 | +0,48 % | Alumis Inc.: Alumis' Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis | Envudeucitinib achieved robust PASI responses by Week 16, with significant continued improvements by Week 24 in PASI 90 (68.0%, 62.1%) and PASI 100 (41.0%, 39.5%)Quality-of-life improvements and itch... ► Artikel lesen | |
| MONTE ROSA THERAPEUTICS | 17,480 | -3,16 % | Monte Rosa Therapeutics, Inc.: Monte Rosa Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates | Positive interim Phase 1 data of NEK7-directed MGD MRT-8102 demonstrated profound CRP reductions in elevated CVD-risk subjects; readout of expanded part 3 CRP PoC trial (now called GFORCE-1) anticipated... ► Artikel lesen | |
| AMYLYX PHARMACEUTICALS | 16,360 | -5,54 % | Gubra A/S: Amylyx Pharmaceuticals Announces Nomination of AMX0318 as a Novel, Long-Acting GLP-1 Receptor Antagonist Development Candidate, Identified in Collaboration with Gubra | AMX0318 selected as development candidate after meeting key criteria, demonstrating a robust chemical stability profile, strong in vitro potency, evidence of in vivo efficacy and tolerability, high... ► Artikel lesen | |
| PHATHOM PHARMACEUTICALS | 12,630 | 0,00 % | Phathom Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results | FLORHAM PARK, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal... ► Artikel lesen | |
| ARCELLX | 114,83 | +0,03 % | Laufende Fusionskontrollverfahren: Gilead Sciences, Foster City, CA/USA; Erwerb sämtlicher Anteile an und Kontrolle über die Arcellx, Redwood City, CA/USA | Datum der Anmeldung:13.03.2026Aktenzeichen:B3-41/26Unternehmen:Gilead Sciences, Foster City, CA/USA; Erwerb sämtlicher Anteile an und Kontrolle über die Arcellx, Redwood City, CA/USAProduktmärkte:Hämatologie... ► Artikel lesen | |
| EVOTEC | 4,530 | +0,09 % | Evotec-Aktie profitiert von Milliarden-Deal: Gilead kauft Tubulis | Der US-Pharmakonzern Gilead setzt seine Einkaufstour im Biotech-Sektor fort und übernimmt das deutsche Krebsforschungsunternehmen Tubulis für bis zu fünf Milliarden Dollar. Die Transaktion zeigt, wie... ► Artikel lesen | |
| BIONTECH | 81,40 | -0,06 % | BioNTech-Wirkstoff BNT323 zeigt Wirkung bei Gebärmutterkrebs | BioNTech hat positive Daten aus einer Phase-2-Studie mit dem Antikörper-Wirkstoff-Konjugat Trastuzumab Pamirtecan (BNT323/DB-1303) veröffentlicht. In einer Kohorte mit stark vorbehandelten Patientinnen... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 19,670 | +1,86 % | Summit Therapeutics Has Scarcity Value In A Crowded Drug Race: Analyst | ||
| BEAM THERAPEUTICS | 27,450 | +4,21 % | Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development | Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and Durably Above the 11 µM Protective AAT Threshold with up to 12 Months of Follow-up... ► Artikel lesen |
Das Unternehmen TRANSTHERA SCIENCES NANJING INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 7,000 Euro und damit -4,11 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TRANSTHERA SCIENCES NANJING INC finden Sie auf Wallstreet Online.